|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS
|
|
|
|
|
|
|
MEVPRO-3 Trial: Testing EZH2 Inhibition in First-Line Metastatic Hormone-Sensitive Prostate Cancer
|
Neeraj Agarwal, MD, FASCO
Neeraj Agarwal describes MEVPRO-3, a Phase III trial randomizing 1,000 metastatic hormone-sensitive prostate cancer patients to ADT plus enzalutamide versus ADT plus enzalutamide plus mevrometostat.
|
|
|
|
|
|
|
|
|
|
|
|
Genomic Risk Stratification in Metastatic Hormone-Sensitive Prostate Cancer with STRATOS-P
|
Martin Schoen, MD, MPH
Martin Schoen describes STRATOS-P, a genomic risk classification derived from next-generation sequencing data on over 2,000 veterans with metastatic hormone-sensitive prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
|
Predicting Docetaxel Benefit with a Genomic Classifier in mHSPC
|
Christopher Sweeney, MBBS
Christopher Sweeney presents a Decipher® genomic classifier analysis of the ENZAMET trial evaluating whether the 22-gene assay can help identify patients with metastatic hormone-sensitive prostate cancer more likely to benefit from adding docetaxel to ADT plus enzalutamide.
|
|
|
|
|
|
|
|
|
|
|
| Genomic and Transcriptomic Correlates of Deep PSA Response in Patients with mHSPC
|
| Emmanuel Antonarakis, MD
|
| Emmanuel Antonarakis discusses a real-world cohort of 525 mHSPC patients, achieving a deep PSA response at 6 months after ADT-based therapy was strongly associated with improved overall survival, and remained an independent predictor of OS on multivariable analysis.Genomically, SPOP alterations were enriched in deep responders, while ZFHX3 alterations were more common in poor responders; no significant transcriptomic differences were observed for emerging targets, supporting the prognostic utility of early PSA depth and select genomic markers in mHSPC.
|
|
|
|
|
|
| Clinical and Transcriptomic Characterization of Metastatic Hormone-Sensitive Prostate Cancer Patients with Low PTEN Expression - Beyond the Abstract
|
| Marta Garcia de Herreros, Natalia Jiménez, and Begoña Mellado
|
| This multicenter study of 350 mHSPC patients shows that low PTEN mRNA expression is an independent adverse prognostic factor, associated with shorter CRPC-free and overall survival, a finding validated in CHAARTED where low PTEN also predicted lack of OS benefit from adding docetaxel to ADT.
|
|
|
|
|
|
| Impact of Androgen Deprivation Therapy (ADT) on KLK2 mRNA Expression and Immunologic Correlates Across Prostate Cancer (PC) Disease States
|
| Deepak Kilari, MD
|
| Deepak Kilari discusses this large real-world genomic/transcriptomic analysis of 7,020 prostate adenocarcinomas, in which KLK2 expression was higher in hormone-sensitive disease than in CRPC, decreased progressively with ADT ± ARPI versus treatment-naïve HSPC, and was highest in primary prostate tumors and in Black/African American patients.
|
|
|
|
|
|
| On-Treatment Serum Prostate Specific Antigen (PSA) and Metastatic Burden at Treatment Start: Landmark Analysis of 7129 Patients Starting Long-Term Androgen Deprivation (ADT) and Randomised in the STAMPEDE Platform Protocol
|
| Mahaz Kayani
|
| In this landmark analysis of 7,129 STAMPEDE patients starting long-term ADT, achieving an on-treatment PSA ≤0.2 ng/mL as early as 6–12 weeks strongly predicted superior 96-month overall survival across metastatic and non-metastatic disease, with progressively worse outcomes at higher PSA thresholds even after multivariable adjustment.
|
|
|
|
|
|
